We are live on ! Find out more
SMMT icon

Summit Therapeutics
SMMT

97 hedge funds and large institutions have $86.3M invested in Summit Therapeutics in 2023 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 36 increasing their positions, 21 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

787% more call options, than puts

Call options by funds: $896K | Put options by funds: $101K

71% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 21

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

43% more capital invested

Capital invested by funds: $60.4M → $86.3M (+$25.9M)

4% more funds holding

Funds holding: 93 → 97 (+4)

0.09% more ownership

Funds ownership: 4.63% → 4.72% (+0.09%)

Holders
97
Holders Change
+4
Holders Change %
+4.3%
% of All Funds
1.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
36
Reduced
21
Closed
6
Calls
$896K
Puts
$101K
Net Calls
+$795K
Net Calls Change
-$1.14M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.89M
2
Morgan Stanley
Morgan Stanley
New York
+$1.76M
3
BlackRock
BlackRock
New York
+$1.61M
4
State Street
State Street
Massachusetts
+$390K
5
N
Nuveen
North Carolina
+$362K

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$5.87M
2
SAM
Shell Asset Management
Netherlands
-$457K
3
CL
CSS LLC
Illinois
-$286K
4
SPIA
Steward Partners Investment Advisory
New York
-$103K
5
Group One Trading
Group One Trading
Illinois
-$68K
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
76
Federated Hermes
Pennsylvania
$32.1K -$11.4K -5,561 -31%
IC
77
Inscription Capital
Texas
$31.3K – – –
HighTower Advisors
78
HighTower Advisors
Illinois
$31K +$24.6K +11,950 New
WAM
79
Worth Asset Management
Texas
$28.6K – – –
Belvedere Trading
80
Belvedere Trading
Illinois
$27.8K +$3.39K +1,646 +18%
SEI Investments
81
SEI Investments
Pennsylvania
$27.1K – – –
SIG
82
Sargent Investment Group
Maryland
$26.1K – – –
AIP
83
Ameritas Investment Partners
Nebraska
$25K – – –
Fidelity Investments
84
Fidelity Investments
Massachusetts
$24.3K +$12.8K +6,233 +202%
MLICM
85
Metropolitan Life Insurance Company (MetLife)
New York
$17.1K – – –
LA
86
LM Advisors
California
$16.2K +$12.8K +6,206 New
OCM
87
Osterweis Capital Management
California
$13.1K – – –
ATC
88
Adirondack Trust Company
New York
$11.3K – – –
Daiwa Securities Group
89
Daiwa Securities Group
Japan
$7K – – –
Russell Investments Group
90
Russell Investments Group
United Kingdom
$6.57K – – –
GWMIA
91
Global Wealth Management Investment Advisory
Florida
$5.22K – – –
LFG
92
Larson Financial Group
Missouri
$4.3K – – –
National Bank of Canada
93
National Bank of Canada
Quebec, Canada
$4.22K – – –
LC
94
Lindbrook Capital
California
$1.38K -$525 -255 -33%
BCPWM
95
Bradley & Co Private Wealth Management
Florida
$522 – – –
S
96
SignatureFD
Georgia
$55 -$5.33K -2,589 -99%
BBA
97
Baker Bros. Advisors
New York
– -$5.87M -3,140,473 Closed
Group One Trading
98
Group One Trading
Illinois
– -$68K -33,074 Closed
AQR Capital Management
99
AQR Capital Management
Connecticut
– -$36K -19,225 Closed
Victory Capital Management
100
Victory Capital Management
Texas
– -$22.9K -12,267 Closed
1 2 3
4
5

SMMT Hedge Fund Activity: Q4 2023 in Review

97 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q4 2023, worth a combined $86.3M — up 43% from $60.4M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new SMMT positions and 6 closed out — a net gain of 4 holders — while 36 added to existing stakes and 21 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.89M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $5.87M sold.

  • 97 institutional investors held Summit Therapeutics (SMMT) as of Q4 2023, up from 93 in Q3 2023.
  • Funds reported $86.3M of Summit Therapeutics stock for Q4 2023, up 43% quarter-over-quarter.
  • 10 funds opened new Summit Therapeutics positions in Q4 2023 and 6 closed out, a net change of +4 holders.
  • The largest Summit Therapeutics buyer in Q4 2023 was Vanguard Group, an estimated $1.89M added.
  • The largest Summit Therapeutics seller in Q4 2023 was Baker Bros. Advisors, an estimated $5.87M sold.

Based on aggregated 13F filings for Q4 2023.